Clinical Trials in Cangzhou, China
4 recruiting
Showing 1–13 of 13 trials
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 1Phase 2
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Colorectal, CancerHead and Neck CancerNon-small Cell Lung Cancer+1 more
Betta Pharmaceuticals Co., Ltd.400 enrolled87 locationsNCT04930432
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
Limited Stage Small Cell Lung Cancer
AstraZeneca200 enrolled26 locationsNCT07161388
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 3
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.144 enrolled35 locationsNCT06860971
Recruiting
Phase 2
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07304739
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled77 locationsNCT07043725
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Not Applicable
Modified Tumor-free Techniques Operation to Cervical Cancer
Cervical Cancer Stage IB2
Peking Union Medical College Hospital524 enrolled13 locationsNCT06836869
Recruiting
Phase 3
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
Phase 3
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
Asthma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.660 enrolled74 locationsNCT06829784
Recruiting
Phase 1
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Advanced Solid TumorNSCLCLymphoma+1 more
Betta Pharmaceuticals Co., Ltd.110 enrolled4 locationsNCT05341557
Recruiting
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
ImageAlzheimer Disease
Ruijin Hospital1,000 enrolled8 locationsNCT06534658